LncRNA expression profiles and validation in keloid and normal skin tissue

  • Authors:
    • Xuebing Liang
    • Lin Ma
    • Xiao Long
    • Xiaojun Wang
  • View Affiliations

  • Published online on: September 22, 2015     https://doi.org/10.3892/ijo.2015.3177
  • Pages:1829-1838
Metrics: HTML 0 views | PDF 0 views     Cited By (CrossRef): 0 citations

Abstract

Keloid is a type of pathological skin scar. Pathogenesis of keloid is complex and is not fully understood. lncRNA can regulate gene expression on different levels. It also participates in cell cycle regulation and cell proliferation. The present study investigated the potential biological function of lncRNA in keloid. We identified differential expression of lncRNAs and mRNAs between 3 pairs of keloid and normal skin tissue by microarray. Differentially expressed lncRNAs were validated by quantitative reverse transcriptase-PCR (qRT-PCR). Gene ontology (GO) and pathway analysis presented the characteristics of associated protein-coding genes. Additionally, a co-expression network of lncRNA and mRNA was constructed to find potential underlying regulation targets. There were 1,731 lncRNAs constantly upregulated and 782 downregulated, 1,079 mRNAs upregulated and 3,282 downregulated in keloid respectively (fold change ≥2.0, p<0.05). We chose, respectively, 3 upregulated and 1 downregulated lncRNA for qRT-PCR and results were consistent with microarray. Moreover, 11 pathways were related with upregulated transcripts and 44 with downregulated in keloid. The co-expression network revealed that one lncRNA was connected with numerous mRNAs, and vice versa. Furthermore, bioinformation analysis suggested that lncRNA CACNA1G-AS1 may be crucial to keloid formation. In conclusion, groups of lncRNAs were aberrantly expressed in keloid compared with normal skin tissue, which indicated that differentially expressed lncRNAs may play a key role in keloid formation. The present study provides new insights into keloid pathology and potential targets for treatment of keloid.

Introduction

Keloid is a benign tumor with characteristics of hyperproliferation of fibroblasts and excessive accumulation of extracellular matrix. This pathological process is often triggered by a skin injury. The lesion invades into the normal skin, and forms a solid nodule which is unable to regress spontaneously (1). Multiple therapeutic methods have been reported, such as surgery, radiotherapy, hormone injection, intense pulsed light (IPL) and intralesional cryotherapy (2,3). However, long-term follow-up has shown a relative high rate of recurrence (4). New therapies have also been applied recently, while safety and compared effect need to be further examined (5,6). To better understand the disease, multiple studies have been conducted to explore the complex pathological mechanism. Nakashima et al (7) identified 4 single nucleotide polymorphism (SNP) loci related to keloid by a multistage genome-wide association study in the Japanese population. Chen et al (8) found 250 upregulated and 152 downregulated genes in keloid compared with normal skin. Moreover, several signaling pathways and transcriptional factors are found associated (9,10). However, the precise linkage gene and pathological process are still controversial.

Long non-coding RNA (lncRNA) refers to a class of non-coding RNA, with length more than 200 nt. LncRNA has been confirmed vital to genomic imprinting, dosage compensation, pluripotency-regulation and organism development (11,12). Although there are no reports on lncRNA in keloid, it does play an important role in skin homeostasis and diseases (13,14). For example, lncRNA such as anti-differentiation non-coding RNA (ANCR) and terminal differentiation-induced non-coding RNA (TINCR) are essential for epidermal stability (15). A deletion of ANCR induces epidermal differentiation spontaneously (16).

Considering that lncRNA has a major role in both normal biological growth and pathological development of diseases, we hypothesize it may also participate in keloid formation. In the present study, we adopted high-throughput microarray screening to compare the differences of lncRNA and mRNA expression profiles between keloid and normal skin tissues. Quantitative RT-PCR followed to confirm the results from microarray. By bioinformation analysis, we used the candidate lncRNAs and their potential related protein-coding genes to construct a coding-non-coding gene co-expression diagram.

Materials and methods

Patients and samples

The present study was approved by the Ethics Committee Board of the Chinese Academy of Medical Sciences and Peking Union Medical College. All the patients involved in this program gave informed consent to the work. We obtained keloid and corresponding normal skin from 16 patients who received surgery in Peking Union Medical College Hospital. None of the patients had received previous treatment for keloid. The diagnosis of keloid was confirmed by the pathological results. During the surgery, keloid was excised completely, and normal skin tissue was obtained after trimming. Tissue was frozen by liquid nitrogen and stored at −80°C.

Total RNA extraction

Total RNA was extracted from the frozen tissue using a TRIzol reagent (Invitrogen, Carlsbad, CA, USA). Each step followed the manufacturer's instructions (Invitrogen). The RNA quality was assessed by NanoDrop ND-1000 (Thermo Fisher Scientific, Waltham, MA, USA), and RNA integrity was assessed by standard denaturing agarose gel electrophoresis.

Microarray profiling

Keloid and normal skin tissue from 3 randomly selected patients were tested in microarray profiling. We used the ArrayStar Human LncRNA/mRNA Expression Microarray version 3.0 (Arraystar, Inc., Rockville, MD, USA). In total, 30,586 lncRNAs and 26,109 coding transcripts can be detected by this microarray. Public transcriptome databases and lncRNA publications were used to construct lncRNAs.

RNA labeling and array hybridization

Sample labeling and array hybridization were performed according to the Agilent One-Color Microarray-Based Gene Expression Analysis protocol (Agilent Technologies) with minor modifications. First, mRNA was purified from total RNA after removal of rRNA (mRNA-ONLY™ Eukaryotic mRNA isolation kit; Epicentre, Madison, WI, USA). Then, each sample was amplified and transcribed into fluorescent cRNA along the entire length of the transcripts without 3′ bias utilizing a random priming method (Quick Amp Labeling kit, One-Color; Agilent p/n 5190-0442). The labeled cRNAs were purified by RNeasy Mini kit (Qiagen p/n 74104). The concentration and specific activity of the labeled cRNAs (pmol Cy3/μg cRNA) were measured by NanoDrop ND-1000. Hybridization adopted Agilent Gene Expression Hybridization kit (Agilent p/n 5188-5242). A total of 1 μg of each labeled cRNA was fragmented by adding 5 μl 10X blocking agent (Agilent p/n 5188-5242) and 1 μl of 25X fragmentation buffer (Agilent p/n 5188-5242), then the mixture was heated at 60°C for 30 min, finally 25 μl 2X GE hybridization buffer (Agilent p/n 5188-5242) was added to dilute the labeled cRNA. A total of 50 μl of hybridization solution was dispensed into the gasket slide and assembled to the lncRNA expression microarray slide. The slides were incubated for 17 h at 65°C in an Agilent hybridization oven (Agilent p/n G2545A). The hybridized arrays were washed, fixed and scanned using the Agilent DNA G2505C microarray.

Data analysis

Agilent Feature Extraction software (version 11.0.1.1) was used to examine acquired array images. Quantile normalization and subsequent data processing were executed using the GeneSpring GX v11.5.1 software package (Agilent Technologies). After quantile normalization of the raw data, lncRNAs and mRNAs, at least 3 out of 6 samples, were chosen for further data analysis. Differentially expressed lncRNAs/mRNAs were classified by a fold change cut-off of 2.0 (upregulated or downregulated) combined with P-value <0.05 as selection criterion. The microarray analysis was performed by Kangcheng Biology Engineering Co., Ltd., (Shanghai, China).

GO and pathway analysis

The Gene Ontology (GO) project offers a controlled vocabulary to label gene and gene product attributes in any organism (http://www.geneontology.org). Three fields are covered in the ontology, which are biological process (BP), cellular component (CC) and molecular function (MF). To avoid more than accidental overlap between the DE list and the GO annotation list exists, Fisher's exact test is applied. P-value represents the significance of GO terms enrichment in the DE genes. Pathway analysis is a functional analysis mapping genes to KEGG pathways. The P-value (EASE-score, Fisher-P value or Hypergeometric-P-value) indicates the significance of the pathway correlated to the conditions. The lower the P-value, the more significant is the pathway. The analysis was performed by Kangcheng Biology Engineering.

The coding-non-coding gene co-expression network

We chose 4 lncRNAs (uc002lfu.1, ENST00000522743, NR_038439 and ENST00000521141) to explore the connection between these lncRNAs and corresponding coding genes. First, the median value of all the transcripts expressed from the same coding gene was selected, while there was no special treatment with the expression value of lncRNA. Secondly, differentially expressed lncRNAs and mRNAs data were screened and taken away from dataset. Thirdly, Pearson correlation coefficient (PCC) between coding gene and lncRNA was calculated using R-value. Fourthly, PCC ≥0.999 was chosen as meaningful related pair. Finally, the network was drawn through Cytoscape (v2.8.1). In the network, we used blue nodes representing coding genes, and red/pink nodes representing lncRNAs. A solid line indicates a positive correlation, and a dashed line a negative correlation.

Quantitative real-time PCR and statistical methods

We used quantitative real-time PCR (qRT-PCR) to confirm the expression levels. Total RNA was extracted from frozen tissue using a TRIzol reagent (Invitrogen Life Technologies) and reverse-transcribed using RT reagent kit (Thermo Fisher Scientific) according to the manufacturer's instructions. Real-time PCR was performed using the SYBR-Green method with ViiA 7 real-time PCR system (Applied Biosystems) following the manufacturer's protocols. Three significantly upregulated lncRNAs (uc002lfu.1, ENST00000522743 and NR_038439) and one downregulated lncRNAs (ENST00000521141) were chosen to test the reproducibility of the data. After further research, NR_038439 drew our attention and was tested in 13 other pairs of tissues. Glyceraldehyde three-phosphate dehydrogenase (GAPDH) acted as endogenous control. Primer sequences were as follows: GAPDH: forward, 5′-GGGAAACTGTGGCGTGAT-3′ and reverse, 5′-GAGTGGGTGTCGCTGTTGA-3′; uc002lfu.1: forward, 5′-TGCTTGATCCAAATAATGCC-3′ and reverse, 5′-TTCAGTCCAGAGATGTGCC-3′; ENST00000522743: forward, 5′-AGACCCAAAGCTGACACCA-3′ and reverse, 5′-ATCTCCCCTCATCCAAACC-3′; NR_038439: forward, 5′-CTGGCAAGGTTGAGTAGGCT-3′ and reverse, 5′-TGCTCCCTTCACACGGTCA-3′; ENST00000521141: forward, 5′-AAGGATGTGGGAGTTTGAGAC-3′ and reverse, 5′-CAGAGGGGAGAGCGTGTTC-3′. The PCR conditions were as follows: PCR reaction under 95°C for 10 min, then 40 cycles of 95°C for 10 sec and 60°C for 60 sec. After setting the concentration of PCR product as 1, all the PCR products were diluted as follows: 1×10−1, 1×10−2, 1×10−3, 1×10−4, 1×10−5, 1×10−6, 1×10−7, 1×10−8 and 1×10−9. As the target genes and housekeeping gene went through PCR separately, the standard curves were drawn based on the dilution. The relative expression (RQ) was obtained through dividing the concentration of target gene by the one of housekeeping gene. The lncRNA expression differences between keloid and normal skin were analyzed using Student's t-test with SPSS (version 16.0; SPSS, Inc., Chicago, IL, USA). A value of P<0.05 was considered significant.

Results

Differentially expressed lncRNAs between keloid and normal skin tissues

The microarray we used in the present study can detect 30,586 lncRNAs and 2,6108 annotated mRNAs from authoritative data sources including ‘RefSeq’, ‘UCSC known-gene’ and ‘Genecode’. We found a total of 16,710 lncRNAs expressed in keloid from lncRNA expression profiling data using microarray analysis (Fig. 1A). Through these data, we compared lncRNA expression levels among 3 pairs of human keloid and their adjacent normal skin tissue (Fig. 1C). There were an average of 2,988 upregulated lncRNAs (range from 2,885 to 3,071) and 1,152 downregulated lncRNAs (range from 1,036 to 1,316), which were significantly differentially expressed (≥2.0-fold) (Fig. 2A). To make the results more precise and reduce the possibility of false positive, we set the screen standard of lncRNA as follows: The abnormal lncRNA should exist in all 3 pairs of tissues. After screening, there were 1,731 constantly upregulated lncRNAs and 782 down-regulated lncRNAs in keloid compared with normal skin. Top 25 differentially expressed lncRNAs are listed in Table I. In the upregulated lncRNAs, the maximum fold change was 24.68, which belonged to uc002lfu.1. Moreover, among the downregulated lncRNAs, ENST00000449151 possessed the maximum fold change, which was 84.18. The dendrogram from hierarchical clustering analysis exhibits relationships among lncRNA expression patterns (Fig. 2C).

Table I

Top 25 differentially expressed lncRNAs with >2-fold change in 3 paired keloid (K) compared with normal skin tissue (N).

Table I

Top 25 differentially expressed lncRNAs with >2-fold change in 3 paired keloid (K) compared with normal skin tissue (N).

Upregulated lncRNAsDownregulated lncRNAs


SeqnameP-valueAbsolute fold change (K vs. N)SeqnameP-valueAbsolute fold change (K vs. N)
uc002lfu.10.00139214124.67823539 ENST000004491510.00037309184.17830568
ENST000004482649.24902E-0523.71568882 ENST000005045094.5935E-0680.75090928
ENST000005227430.00396470623.32120992TCONS_000144470.00274368355.75905607
NR_0027850.00024580619.67171045 ENST000005088840.00071804643.04190122
ENST000005637540.00227882318.09086601 ENST000005435120.00115716229.62729347
ENST000005680310.00118202616.43215739NR_0371665.8668E-0527.86637043
ENST000004304680.00044069415.99398905NR_0497760.00035601225.44496144
ENST000005687670.00265279115.40462545 ENST000005079500.0009724425.35162231
ENST000005648320.00056126415.3230045 ENST000004323770.00408528423.58314193
ENST000005240450.00061758314.35734021NR_0462580.00081847922.51173429
NR_0464380.00106198713.5487176NR_0462590.00138950422.22674064
ENST000005144680.00974771413.40050409 ENST000004253990.00955938919.76933951
ENST000004391860.00029885813.26738526uc002nrq.30.00039450919.66993157
ENST000003993420.01400823713.24836573 ENST000005240124.96526E-0519.12630922
ENST000004405700.00188367412.84056697uc001gzl.30.00075596518.64074653
ENST000004441140.00082762612.38834219 ENST000005653080.00052099816.33469184
ENST000005189320.00729126411.83886059NR_0340590.00059088315.93734199
NR_0384390.00117337611.63954238 ENST000005296670.00122751414.76394367
ENST000004257110.00055464211.11258257TCONS_000208430.00177985113.8754485
NR_0339970.00194995610.53634973TCONS_000051940.00064019113.76677473
ENST000004381540.00576269710.15674579 ENST000005139150.00228457513.24861031
AL5127230.00428710710.09486468uc001uum.30.0048469212.76120477
ENST000004240940.0002249469.997377279 ENST000005211410.00028833412.44615316
ENST000004895200.0042078649.470087791 ENST000005211880.0003827212.39901463
TCONS_000234860.0018314019.387344686NR_0278561.6202E-0512.11977043

[i] P-values <0.05 are considered significant.

Differentially expressed mRNAs between keloid and normal skin tissues

The mRNA expression profiling data showed a total of 18,788 mRNAs in keloid using microarray analysis (Fig. 1B). After comparing the three keloids with their paired adjacent normal skin tissue (Fig. 1D), we found an average of 1,799 upregulated mRNAs (range from 1,643 to 1,975) and 3,784 downregulated mRNAs (range 3,516 from 4,035) which were significantly differentially expressed (fold change ≥2.0) (Fig. 2B). In the three paired samples, 1,079 mRNAs were consistently upregulated and 3,282 were consistently downregulated. Top 25 differentially expressed mRNAs are listed in Table II. In the upregulated mRNAs, NM_003014 possessed the maximum fold change, which was 18.22. In the downregulated mRNAs, NM_053283 had the maximum fold change, which was 6366.20. The clustering analysis showed relationships among the mRNA expression patterns, which were present in the samples (Fig. 2D).

Table II

Top 25 differentially expressed mRNAs with >2-fold change in 3 paired keloid (K) compared with normal skin tissue (N).

Table II

Top 25 differentially expressed mRNAs with >2-fold change in 3 paired keloid (K) compared with normal skin tissue (N).

Upregulated lncRNAsDownregulated lncRNAs


SeqnameP-valueAbsolute fold change (K vs. N)SeqnameP-valueAbsolute fold change (K vs. N)
NM_0030140.00076603418.22751605NM_0532830.0008684726366.203092
ENST000004379360.0031295516.04025716NM_0026527.5475E-062026.938265
NM_2073730.00110818214.5670146NM_0024110.0007706761643.833883
NM_0010108760.0028838611.99403154NM_0032510.000312511220.2447826
ENST000003687890.00123547511.63268318NM_1523100.001096438208.8875889
NM_0011682430.0004928729.6787663NM_0010805260.000480409176.4587386
NM_0058240.0006017089.311818897 ENST000002355476.3784E-06174.2506749
ENST000003543730.0006016889.000401956NM_0159736.96809E-05173.3800147
ENST000003705320.0047543618.164392456 ENST000003121507.50899E-07172.9050825
ENST000003593200.0023911077.870021989NM_0319620.000808876154.1275941
NM_0011350.0007144467.627240018NM_1815350.001212281150.8484539
NM_0011451430.0027481017.609122032NM_0070080.000180465148.9725592
NM_0011990.0038009587.513524934 ENST000003016562.65207E-05146.1537903
NM_0123640.0171023487.281585238NM_0331859.90898E-06131.6408041
NM_0011597090.0104062056.717817641NM_0014820.000181169106.3194866
NM_0326430.0011268096.638854499NM_0331870.00010745377.30322869
ENST000004356070.0070401866.635851494NM_1986923.8766E-0576.91933758
NM_1768910.0015310536.567488034NM_0319640.00039917276.61683722
ENST000003896230.0003091486.508019919NM_1991610.00024235372.38119393
NM_0182500.0010957946.407558892NM_1457920.00049702771.81391287
NM_0010054660.0025400386.395862838 ENST000003607700.0002627270.84177719
NM_0056510.011396656.349965704NM_0307540.00185747467.74012607
ENST000003193310.0001790286.191758346 ENST000001823778.80738E-0562.45728419
NM_2033710.0004998946.113256778NM_0011233870.00311906961.24489543
NM_0011679160.0043786696.091668213 ENST000003687440.00021951859.85728897

[i] P-values <0.05 is considered significant.

GO analysis and pathway analysis

GO analysis was used to analyze the main function of the closest coding genes according to the GO database. We found that in upregulated transcripts from keloid, the highest enriched GOs were biological regulation (biological process) (Fig. 3A), membrane (cellular component) (Fig. 3B), and receptor activity (molecular function) (Fig. 3C). Also, in the downregulated transcripts, the highest enriched GOs were cellular process (biological process) (Fig. 3D), cell part/cell (cellular component) (Fig. 3E), and binding (molecular function) (Fig. 3F). In pathway analysis, there were a total of 11 pathways related with upregulated transcripts in keloid (Fig. 4A). The most enriched network was Neuroactive ligand-receptor interaction, Homo sapiens (human). Also, 44 pathways were found related with downregulated transcripts in keloid (Fig. 4B). Among them, the most enriched network was valine, leucine and isoleucine degradation, Homo sapiens (human). It is interesting that calcium pathway signaling was one of the items above. Considering calcium played a vital role in wound healing, a common process in keloid formation and calcium ion influx inhibitor was used for keloid treatment (17), calcium pathway signaling was important in pathological behavior.

Construction of the co-expression network

We built a co-expression network using correlation analysis between differentially expressed lncRNAs (uc002lfu.1, ENST00000522743, NR_038439, ENST00000521141) and mRNAs (Fig. 5). LncRNAs and mRNAs with Pearson correlation coefficients not less than 0.999 were chosen to draw the network by Cytoscape (v2.8.1). There were 4 lncRNAs and 298 mRNAs in this network, 302 nodes possessed 304 pairs of connections between lncRNAs and mRNAs. The network was complex and indicated that one lncRNA was associated with multiple mRNAs, and vice versa.

Validation of the microarray finding by qRT-PCR

In order to validate the results from microarray, we selected 3 upregulated (uc002lfu.1, ENST00000522743 and NR_038439) and 1 downregulated lncRNA (ENST00000521141) from the differentially expressed lncRNA profile, then performed quantitative RT-PCR in original tissues. All of the chosen lncRNAs exhibited abundant expression and had significant changes between the two groups in microarray. The results of qRT-PCR were consistent with microarray data (Fig. 6A). Because calcium signaling pathway may be related with keloid, we chose NR_038439 (lncRNA CACNA1G-AS1), an antisense RNA to CACNA1G which encodes a subtype of T-type Ca2+ channels, and performed qRT-PCR in another 13 pairs of examples. The result was consistent (P<0.05) (Fig. 6B).

Discussion

In the present study, we have identified a group of lncRNAs and mRNAs, which had abnormal expression in keloid. To the best of our knowledge, this is the first large-scale lncRNA screening, and study of its role in keloid. Non-coding RNA has been investigated in keloid, and there are many exciting reports (18). Liu et al (19) used miRNA microarray in 13 couples of keloid and normal skin, and a total of 32 miRNAs were found with abnormal expression in keloid. They also found that miR-21 could affect apoptosis of keloid fibro-blast by negatively regulating the expression of PTEN (20). Compared with microRNA, lncRNA is larger, and has more complex structure. Deregulated expression of lncRNA will disrupt cellular physiology, and then lead to pathologies (21). Thus, we presumed that it could be vital to the formation of keloid.

LncRNAs are important in both skin homeostasis and diseases. When TINCR is deficient, epidermis is found with abnormal morphological characteristics by absence of keratohyalin granules and lamellar bodies, which are essential for protecting skin from environmental damage (22). On the other hand, lncRNAs are also crucial in cutaneous malignancies. Vitamin D and its receptor (VDR) are indispensable for preventing epidermal tumor (23), partially due to VDR keeping a balance between oncogenic lncRNAs and tumor suppressors (24). After comparing lncRNAs in melanoma cell lines, melanocytes and keratinocytes, SPRY4-IT1 was found upregulated in melanoma cells (25). Following knockdown, the invasion and proliferation of melanoma ceased, and the apoptosis of the cells increase. Mazar and his colleagues found that Lipin 2 was a binding protein to SPRY4-IT1 (26). They proposed that an abnormal expression of SPRY4-IT1 led to an increased level of Lipin 2, which may cause the disease. The mechanism of how lncRNAs function has not been fully studied, yet several models have been proposed. LncRNAs can perform as molecular signals, decoys, guiding certain protein to specific location and scaffolds (27). Therefore, further research on lncRNA characterization will help us understand the mechanism of keloid formation, and enable development of personalized therapeutic strategies.

By performing microarray profiling, we found 16,710 lncRNAs and 18,788 mRNAs in keloid. Among them, 1,731 lncRNAs were constantly upregulated and 782 were downregulated, whereas, 1,079 mRNAs were consistently upregulated and 3,282 were downregulated. GO analysis showed that upregulated lncRNAs were enriched in biological regulation, while downregulated ones were enriched in cellular process and metabolic process. These also had a tight connection with keloid formation. Using KEGG pathway analysis, we found an obvious change in ECM-receptor interaction, calcium signaling pathway, focal adhesion and mRNA surveillance pathway.

After validation by qRT-PCR, lncRNA CACNA1G-AS1 was proven to have high expression in a total of 16 keloid tissues. CACNA1G-AS1 is an antisense RNA to CACNA1G. CACNA1G encodes Cav3.1, which is a subtype of T-type Ca2+ channels (28). Cav3.1 was found to be a tumor suppressor (29,30). As far as we know, there are no reports on the function of CACNA1G-AS1. On the one hand, we have started to build models to explore its potential function. On the other hand, we are trying to find out how other antisense lncRNAs interact with their target genes, which may give us an inspiration on the current dilemma.

Antisense RNAs are defined as RNAs transcribed either from opposite strand of a protein coding gene or a sense strand-derived RNA (31). They can either positively or negatively modulate protein-coding genes (32). Xue et al (33) found that in bladder cancer cells, lncRNA MDC1-AS can inhibit malignant cell performance by upregulating the expression of MDC1, a cancer suppressing gene, in both mRNA and protein levels. Our mRNA microarray result showed that CACNA1G also exhibited higher expression level in keloid. Thus, we presumed that CACNA1G-AS1 might regulate the pathological process in keloid through interacting with CACNA1G. More experiments are needed to explore the hypothesis. The L-type calcium channel blocker verapamil, has already been used in clinical treatment for keloid and proven effective (34). An 18-month follow-up of clinical study showed that in a group of patients who received intralesional verapamil hydrochloride injections after surgery, keloid was cured in 54% of them, compared to 18% in the control group who received the same therapy except verapamil (35). Some researchers believe that hypertension is one of the reasons that may cause keloid, thus anti-hypertension pharmaceuticals such as verapamil is useful (36). Verapamil can also decrease the production of cytokines such as IL-6 and VEGF in central keloid fibroblasts, which are responsible for irregular proliferation of keloid fibroblasts (37). Based on these theories, we propose that Cav3.1 blocker may also be valid in treating keloid in a similar way.

Besides the CACNA1G, we found 26 other genes related to CACNA1G-AS1 in the co-expression network. They were RABGAP1,TTC18,PDPN,TUBB6,WDR3,ACP1,WFDC12, DPT, SIGMAR1, LGALSL, IBSP, ODF3, ZNF429, CHMP5, RNF6, ALOX15B, TF, SLC35F5, FGFBP1, NPL, VIMP, TRC, CCT7, SFRP4, CATSPER2 and CKAP5. Many of them are involved in cell proliferation and preventing cell apoptosis, which are commonly seen in keloid. Dermatopontin (DPT) participates in wound healing by activating fibronectin and improving cell adhesion (38). CHMP5, a multivesicular body, can inhibit cell apoptosis. When expression of CHMP5 is inhibited in leukemic cells, caspase-3 is activated, and apoptosis is stimulated (39). FGFBP1, known as FGFBP, is upregulated in several types of tumors and critical for tumor angiogenesis (40). More research should be done to establish related regulation mechanisms between these coding and noncoding genes.

In conclusion, we profiled differentially expressed lncRNAs and mRNAs in keloid and normal skin tissue. Further information on the candidate lncRNAs and their associated protein-coding genes were also studied. CACNA1G-AS1 was upregulated in keloid, and it may be important in keloid formation. However, further studies of the possible mechanism are required. Our findings indicate that lncRNAs are involved in the pathological process of keloid, which may help to explain the mechanism of keloid formation.

Acknowledgements

The present study was supported by a grant from the National Natural Science Foundation of China (NSFC) (no. 81071571).

References

1 

Halim AS, Emami A, Salahshourifar I and Kannan TP: Keloid scarring: Understanding the genetic basis, advances, and prospects. Arch Plast Surg. 39:184–189. 2012. View Article : Google Scholar : PubMed/NCBI

2 

van Leeuwen MC, van der Wal MB, Bulstra AE, Galindo-Garre F, Molier J, van Zuijlen PP, van Leeuwen PA and Niessen FB: Intralesional cryotherapy for treatment of keloid scars: A prospective study. Plast Reconstr Surg. 135:580–589. 2015. View Article : Google Scholar : PubMed/NCBI

3 

Erol OO, Gurlek A, Agaoglu G, Topcuoglu E and Oz H: Treatment of hypertrophic scars and keloids using intense pulsed light (IPL). Aesthetic Plast Surg. 32:902–909. 2008. View Article : Google Scholar : PubMed/NCBI

4 

Juckett G and Hartman-Adams H: Management of keloids and hypertrophic scars. Am Fam Physician. 80:253–260. 2009.PubMed/NCBI

5 

Mseddi M, Mesrati H, Ktaari S, Amouri M, Chaaben H, Boudaya S and Turki H: Treatment of keloid with phenol: A new therapy. Ann Dermatol Venereol. 141:493–499. 2014.(In French). View Article : Google Scholar : PubMed/NCBI

6 

van Leeuwen MC, Bulstra AE, van Leeuwen PA and Niessen FB: A new argon gas-based device for the treatment of keloid scars with the use of intralesional cryotherapy. J Plast Reconstr Aesthet Surg. 67:1703–1710. 2014. View Article : Google Scholar : PubMed/NCBI

7 

Nakashima M, Chung S, Takahashi A, Kamatani N, Kawaguchi T, Tsunoda T, Hosono N, Kubo M, Nakamura Y and Zembutsu H: A genome-wide association study identifies four susceptibility loci for keloid in the Japanese population. Nat Genet. 42:768–771. 2010. View Article : Google Scholar : PubMed/NCBI

8 

Chen W, Fu X, Sun X, Sun T, Zhao Z and Sheng Z: Analysis of differentially expressed genes in keloids and normal skin with cDNA microarray. J Surg Res. 113:208–216. 2003. View Article : Google Scholar : PubMed/NCBI

9 

Unahabhokha T, Sucontphunt A, Nimmannit U, Chanvorachote P, Yongsanguanchai N and Pongrakhananon V: Molecular signalings in keloid disease and current therapeutic approaches from natural based compounds. Pharm Biol. 53:457–463. 2015. View Article : Google Scholar

10 

Murao N, Seino K, Hayashi T, Ikeda M, Funayama E, Furukawa H, Yamamoto Y and Oyama A: Treg-enriched CD4+ T cells attenuate collagen synthesis in keloid fibroblasts. Exp Dermatol. 23:266–271. 2014. View Article : Google Scholar : PubMed/NCBI

11 

Kung JT, Colognori D and Lee JT: Long noncoding RNAs: Past, present, and future. Genetics. 193:651–669. 2013. View Article : Google Scholar : PubMed/NCBI

12 

Bonasio R and Shiekhattar R: Regulation of transcription by long noncoding RNAs. Annu Rev Genet. 48:433–455. 2014. View Article : Google Scholar : PubMed/NCBI

13 

He Y, Meng XM, Huang C, Wu BM, Zhang L, Lv XW and Li J: Long noncoding RNAs: Novel insights into hepatocelluar carcinoma. Cancer Lett. 344:20–27. 2014. View Article : Google Scholar

14 

Martens-Uzunova ES, Böttcher R, Croce CM, Jenster G, Visakorpi T and Calin GA: Long noncoding RNA in prostate, bladder, and kidney cancer. Eur Urol. 65:1140–1151. 2014. View Article : Google Scholar : PubMed/NCBI

15 

Hombach S and Kretz M: The non-coding skin: Exploring the roles of long non-coding RNAs in epidermal homeostasis and disease. BioEssays. 35:1093–1100. 2013. View Article : Google Scholar : PubMed/NCBI

16 

Kretz M, Webster DE, Flockhart RJ, Lee CS, Zehnder A, Lopez-Pajares V, Qu K, Zheng GX, Chow J, Kim GE, et al: Suppression of progenitor differentiation requires the long noncoding RNA ANCR. Genes Dev. 26:338–343. 2012. View Article : Google Scholar : PubMed/NCBI

17 

Boggio RF, Freitas VM, Cassiola FM, Urabayashi M and Machado-Santelli GM: Effect of a calcium-channel blocker (verapamil) on the morphology, cytoskeleton and collagenase activity of human skin fibroblasts. Burns. 37:616–625. 2011. View Article : Google Scholar

18 

Kashiyama K, Mitsutake N, Matsuse M, Ogi T, Saenko VA, Ujifuku K, Utani A, Hirano A and Yamashita S: miR-196a down-regulation increases the expression of type I and III collagens in keloid fibroblasts. J Invest Dermatol. 132:1597–1604. 2012. View Article : Google Scholar : PubMed/NCBI

19 

Liu Y, Yang D, Xiao Z and Zhang M: miRNA expression profiles in keloid tissue and corresponding normal skin tissue. Aesthetic Plast Surg. 36:193–201. 2012. View Article : Google Scholar

20 

Liu Y, Wang X, Yang D, Xiao Z and Chen X: MicroRNA-21 affects proliferation and apoptosis by regulating expression of PTEN in human keloid fibroblasts. Plast Reconstr Surg. 134:561e–573e. 2014. View Article : Google Scholar : PubMed/NCBI

21 

Di Gesualdo F, Capaccioli S and Lulli M: A pathophysiological view of the long non-coding RNA world. Oncotarget. 5:10976–10996. 2014. View Article : Google Scholar : PubMed/NCBI

22 

Kretz M: TINCR, staufen1, and cellular differentiation. RNA Biol. 10:1597–1601. 2013. View Article : Google Scholar : PubMed/NCBI

23 

Bikle DD: The vitamin D receptor: A tumor suppressor in skin. Discov Med. 11:7–17. 2011.PubMed/NCBI

24 

Jiang YJ and Bikle DD: LncRNA profiling reveals new mechanism for VDR protection against skin cancer formation. J Steroid Biochem Mol Biol. 144pa:87–90. 2014.

25 

Wan DC and Wang KC: Long noncoding RNA: Significance and potential in skin biology. Cold Spring Harb Perspect Med. 4:1–10. 2014. View Article : Google Scholar

26 

Mazar J, Zhao W, Khalil AM, Lee B, Shelley J, Govindarajan SS, Yamamoto F, Ratnam M, Aftab MN, Collins S, et al: The functional characterization of long noncoding RNA SPRY4-IT1 in human melanoma cells. Oncotarget. 5:8959–8969. 2014. View Article : Google Scholar : PubMed/NCBI

27 

Wang KC and Chang HY: Molecular mechanisms of long noncoding RNAs. Mol Cell. 43:904–914. 2011. View Article : Google Scholar : PubMed/NCBI

28 

Fukunaga K: Cognitive Function and Calcium. Cognitive improvement through T type calcium channel stimulation. Clin Calcium. 25:247–254. 2015.(In Japanese). PubMed/NCBI

29 

Toyota M, Ho C, Ohe-Toyota M, Baylin SB and Issa JP: Inactivation of CACNA1G, a T-type calcium channel gene, by aberrant methylation of its 5′ CpG island in human tumors. Cancer Res. 59:4535–4541. 1999.PubMed/NCBI

30 

Ohkubo T and Yamazaki J: T-type voltage-activated calcium channel Cav3.1, but not Cav3.2, is involved in the inhibition of proliferation and apoptosis in MCF-7 human breast cancer cells. Int J Oncol. 41:267–275. 2012.PubMed/NCBI

31 

Villegas VE and Zaphiropoulos PG: Neighboring gene regulation by antisense long non-coding RNAs. Int J Mol Sci. 16:3251–3266. 2015. View Article : Google Scholar : PubMed/NCBI

32 

Zhang ZZ, Shen ZY, Shen YY, Zhao EH, Wang M, Wang CJ, Cao H and Xu J: HOTAIR long noncoding RNA promotes gastric cancer metastasis through suppression of Poly r(C) Binding Protein (PCBP) 1. Mol Cancer Ther. 14:1162–1170. 2015. View Article : Google Scholar : PubMed/NCBI

33 

Xue Y, Ma G, Zhang Z, Hua Q, Chu H, Tong N, Yuan L, Qin C, Yin C, Zhang Z, et al: A novel antisense long noncoding RNA regulates the expression of MDC1 in bladder cancer. Oncotarget. 6:484–493. 2015. View Article : Google Scholar :

34 

Ledon JA, Savas J, Franca K, Chacon A and Nouri K: Intralesional treatment for keloids and hypertrophic scars: A review. Dermatol Surg. 39:1745–1757. 2013. View Article : Google Scholar : PubMed/NCBI

35 

D'Andrea F, Brongo S, Ferraro G and Baroni A: Prevention and treatment of keloids with intralesional verapamil. Dermatology. 204:60–62. 2002. View Article : Google Scholar : PubMed/NCBI

36 

Huang C and Ogawa R: Pharmacological treatment for keloids. Expert Opin Pharmacother. 14:2087–2100. 2013. View Article : Google Scholar : PubMed/NCBI

37 

Giugliano G, Pasquali D, Notaro A, Brongo S, Nicoletti G, D'Andrea F, Bellastella A and Sinisi AA: Verapamil inhibits interleukin-6 and vascular endothelial growth factor production in primary cultures of keloid fibroblasts. Br J Plast Surg. 56:804–809. 2003. View Article : Google Scholar : PubMed/NCBI

38 

Wu W, Okamoto O, Kato A, Matsuo N, Nomizu M, Yoshioka H and Fujiwara S: Dermatopontin regulates fibrin formation and its biological activity. J Invest Dermatol. 134:256–263. 2014. View Article : Google Scholar

39 

Wang H, Liu J, Wang F, Chen M, Xiao Z, Ouyang R, Fei A, Shen Y and Pan S: The role of charged multivesicular body protein 5 in programmed cell death in leukemic cells. Acta Biochim Biophys Sin (Shanghai). 45:383–390. 2013. View Article : Google Scholar

40 

Abuharbeid S, Czubayko F and Aigner A: The fibroblast growth factor-binding protein FGF-BP. Int J Biochem Cell Biol. 38:1463–1468. 2006. View Article : Google Scholar

Related Articles

Journal Cover

November 2015
Volume 47 Issue 5

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Liang, X., Ma, L., Long, X., & Wang, X. (2015). LncRNA expression profiles and validation in keloid and normal skin tissue. International Journal of Oncology, 47, 1829-1838. https://doi.org/10.3892/ijo.2015.3177
MLA
Liang, X., Ma, L., Long, X., Wang, X."LncRNA expression profiles and validation in keloid and normal skin tissue". International Journal of Oncology 47.5 (2015): 1829-1838.
Chicago
Liang, X., Ma, L., Long, X., Wang, X."LncRNA expression profiles and validation in keloid and normal skin tissue". International Journal of Oncology 47, no. 5 (2015): 1829-1838. https://doi.org/10.3892/ijo.2015.3177